VAL001 – Business Opportunity Summary. A. Mansson, Non-Executive Director, Respiratorius AB. Respiratorius AB develops new and effective candidate drugs for treatment of cancer, COPD and asthma. VAL001 is an orphan drug designated asset that is phase III ready. The indication is Diffuse Large B-Cell Lymphoma (DLBCL).
Respiratorius AB (publ) develops candidate drugs with the goal of launching drugs to treat aggressive lymphoma (cancer).
Scheeletorget 1, 223 81 Lund, Sweden
+46 70 922 41 40